Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: Duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation

被引:25
作者
Birkeland, SA
Hamilton-Dutoit, S
Bendtzen, K
机构
[1] Odense Univ Hosp, Dept Nephrol, DK-5000 Odense, Denmark
[2] Aarhus Univ Hosp, Inst Pathol, DK-8000 Aarhus, Denmark
[3] Natl Univ Hosp, Rigshosp, Inst Inflammat Res IIR7521, Copenhagen, Denmark
关键词
D O I
10.1097/01.TP.0000072015.08302.E9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Posttransplant lymphoproliferative disorder (PTLD) can be resolved in many transplant patients by the reduction or cessation of immunosuppression, after which many grafts continue to function as the result of a form of operational tolerance. When graft function deteriorates, retransplantation may be an option. Cytokines such as interleukin (IL)-10 and IL-18 may play a role in PTLD tolerance induction and tumor regression. We report long-term follow-up on the duration of graft tolerance and the course of retransplantation in a series of patients who underwent kidney transplantation and demonstrated PTLD, and in whom we were able to perform IL-18 analyses. Results. Patients were followed for up to 7 years after PTLD diagnosis. Treatment consisted of immunosuppression cessation with radiation therapy in cases with overt monomorphic lymphomas. All patients' PTLDs were resolved, and all patients but one (whose graft was removed) demonstrated a period of operational graft tolerance of up to 5 years. Five patients underwent retransplantation without sign of recurrence of the PTLD up to 3 years after transplantation. In the eight patients analyzed, IL-18 increased significantly during PTLD regression and follow-up in those with long-term operational tolerance. Conclusion. We report on a series of patients with resolved PTLDs demonstrating long-term recurrence-free survival, of whom most experienced a long period of operational graft tolerance. IL-18 seems to play a role in the resolution of the PTLDs. Five patients underwent retransplantation with standard immunosuppression without recurrence. A previous diagnosis of PTLD should not be regarded as a contraindication for later retransplantation.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 31 条
[1]  
[Anonymous], 1985, Lancet, V2, P1163
[2]   Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation [J].
Birkeland, SA ;
Bendtzen, K ;
Moller, B ;
Hamilton-Dutoit, S ;
Andersen, HK .
TRANSPLANTATION, 1999, 67 (06) :876-881
[3]   Interleukin-10 and Epstein-Barr virus-induced posttransplant lymphoproliferative disorder [J].
Birkeland, SA ;
Bendtzen, K .
TRANSPLANTATION, 1996, 61 (09) :1425-1426
[4]  
Birkeland SA, 1995, TRANSPLANT P, V27, P3467
[5]   Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. [J].
Birkeland, SA .
TRANSPLANTATION, 1998, 66 (09) :1207-1210
[6]  
Birkeland SA, 1998, SCAND J INFECT DIS, V30, P221, DOI 10.1080/00365549850160837
[7]   Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: Use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol [J].
Birkeland, SA ;
Andersen, HK ;
Hamilton-Dutoit, SJ .
TRANSPLANTATION, 1999, 67 (09) :1209-1214
[8]   POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE OF THE LIVER SUCCESSFULLY TREATED BY RETRANSPLANTATION [J].
CHACHAP, P ;
FILHO, EC ;
PORTA, G ;
MIURA, I ;
ZERBINI, MC ;
GAYOTTO, LC ;
MAKSOUD, JG .
TRANSPLANTATION, 1991, 52 (04) :736-737
[9]  
CHEYNE AJ, 1987, LANCET, V2, P456
[10]   Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis [J].
Coughlin, CM ;
Salhany, KE ;
Wysocka, M ;
Aruga, E ;
Kurzawa, H ;
Chang, AE ;
Hunter, CA ;
Fox, JC ;
Trinchieri, G ;
Lee, WMF .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (06) :1441-1452